Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu

The Effect of Manuka Eye Drops on Tear Film Properties

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03622619
Recruitment Status : Completed
First Posted : August 9, 2018
Last Update Posted : April 25, 2019
Sponsor:
Information provided by (Responsible Party):
Jacqueline Tan-Showyin, The University of New South Wales

Brief Summary:
Traditionally, Manuka honey has been used to combat against bacteria and reduce inflammation (the body's way of reacting to infection, irritation or other injury). Due to the inflammatory nature of dry eye, Manuka eye drops show promise as a treatment for dry eye disease. The aim of this research is to compare the effects of two over the counter eye drops that are used to treat dry eye conditions over a one month period.

Condition or disease Intervention/treatment Phase
Dry Eye Syndrome Other: Optimel Antibacterial Manuka+ Dry Eye Drops Other: Systane Ultra Lubricating Eye Drops Not Applicable

Detailed Description:
The aim of the present study is to conduct a randomised clinical trial to compare the effect on tear film properties and dry eye signs and symptoms of Optimel Manuka eye drops compared to Systane Ultra, a widely available over the counter aqueous tear supplement as a control eye drop. This investigation will involve a minimum of 40 participants who have dry eye, who are randomly put into two groups receiving either Optimel Manuka drops or Systane Ultra used three times daily for one month. Both of these products are commercially available in Australia. Results from this study will inform practitioners as to the potential benefits of Manuka eye drops on tear film characteristics and signs and symptoms of dry eye.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 46 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double (Participant, Investigator)
Primary Purpose: Treatment
Official Title: The Effect of Manuka Eye Drops on Tear Film Properties
Actual Study Start Date : August 13, 2018
Actual Primary Completion Date : October 30, 2018
Actual Study Completion Date : October 30, 2018

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Tears
Drug Information available for: Systane

Arm Intervention/treatment
Experimental: Manuka eye drops Other: Optimel Antibacterial Manuka+ Dry Eye Drops
Leptospermum sp Honey 165mg/g

Active Comparator: Systane Ultra Other: Systane Ultra Lubricating Eye Drops
Polyethylene glycol 400 0.4% and propylene glycol 0.3%




Primary Outcome Measures :
  1. Lipid layer thickness [ Time Frame: 28 days ]
    Measured in nanometers using a Lipiview II

  2. Tear evaporation rate [ Time Frame: 28 days ]
    Measured using a Modified Vapometer

  3. Fluorescein tear break-up time [ Time Frame: 28 days ]
    Measured in seconds using a stop watch


Secondary Outcome Measures :
  1. Subjective comfort [ Time Frame: 28 days ]
    Measured using questionnaires in paper format



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Able to read and comprehend English and give informed consent as demonstrated by signing a record of informed consent;
  • General population aged 18 years and over;
  • In good general health;
  • Subjectively experiencing dry eye symptoms (e.g. burning, irritation, and discomfort due to dryness of the eye or exposure to wind or sun). Participants will be selected based on a minimum OSDI score of 13 points (1).
  • Willing to discontinue CL wear for 1 week before first visit and continue to do so until the conclusion of the study;
  • Participant is willing to discontinue their use of any previous conventional dry eye treatment method commenced before the study throughout the study;
  • Willing to comply with the dosage and study visit schedule as directed by the investigator;
  • No planned changes to diet and willing not to substantially alter their usual diet for the duration of the study, including their typical intake of fish, green tea or oral supplements known to have anti-inflammatory properties;
  • Willingness to notify the study investigator if instructed to alter their diet by health/medical practitioner.

Exclusion Criteria:

  • Allergy to benzoic acid preservatives;
  • Allergy to honey products;
  • Active anterior eye disease/ infection, inflammation/allergy that requires ocular medical treatment;
  • Eye injury or surgery in the past 6 months including chemical burns, penetrating injuries, traumatic iritis, orbital fractures, laser surgery, strabismus surgery, cataract or any other intraocular surgeries;
  • Soft contact lens, rigid gas permeable, orthokeratology lens wearer within one week prior to the study and during the study.
  • Use of any of the following medications (including steroids) up to 12 weeks prior to start of the study or during the course of the study:

    • Ocular medication, category S3 and above;
    • Any systemic or topical medications that will affect ocular physiology e.g. anti-acne medications such as Roaccutane and corticosteroid or immunosuppressant medications such as Hydrocortisone, Prednisolone and antihistamine medications such as Claritine;
  • Any systemic disease that may affect ocular health e.g. Graves disease, and auto-immune diseases such as ankolysing spondylitis, multiple sclerosis and systemic lupus erythematosis;
  • Epilepsy or history of migraines exacerbated by flashing, strobe-like lights.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03622619


Locations
Layout table for location information
Australia, New South Wales
School of Optometry and Vision Science
Sydney, New South Wales, Australia, 2050
Sponsors and Collaborators
The University of New South Wales
Investigators
Layout table for investigator information
Principal Investigator: Jacqueline Tan, PhD University of New South Wales
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Layout table for additonal information
Responsible Party: Jacqueline Tan-Showyin, Senior Research Fellow, The University of New South Wales
ClinicalTrials.gov Identifier: NCT03622619    
Other Study ID Numbers: SOVS2018-501
First Posted: August 9, 2018    Key Record Dates
Last Update Posted: April 25, 2019
Last Verified: April 2019
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No
Plan Description: Study results will be made available in the form of summaries

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Product Manufactured in and Exported from the U.S.: Yes
Additional relevant MeSH terms:
Layout table for MeSH terms
Dry Eye Syndromes
Lacrimal Apparatus Diseases
Eye Diseases
Anti-Bacterial Agents
Ophthalmic Solutions
Lubricant Eye Drops
Pharmaceutical Solutions
Anti-Infective Agents